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To facilitate  administration  of  praziquantel  (PZQ)  to African  infants  and  preschool-aged
children  using  a dose  pole,  the performance  of  two downwardly  extended  versions  (the
ﬁrst created  in  2010  using  biometric  data  from  Uganda  alone  and  the  second  version  cre-
ated here  using  data  from  36  countries)  was  assessed  against  height/weight  data  from  a
total  of  166  210  preschool-aged  children  (≤6  year  olds)  from  36 African  countries.  New
and  optimized  thresholds  for  PZQ  tablet  administration  at one  tablet  (600  mg),  ¾ and  ½
tablet  divisions  are  suggested  here.  Both  dose  poles  investigated  estimated  an  acceptable
PZQ dosage  (30–60  mg/Kg)  for  more  than  95%  of  children.  Extension  and  optimization  of
the current  PZQ  dose  pole,  followed  by  theoretical  validation  using  biometric  data  from
preschool-aged  children  (0–6  years  of  age, 60–110  cm  in  height)  from  36  African  countriesablet pole
reatment pole
will  help  future  mass  drug  administration  campaigns  incorporate  younger  children.  This
newly  optimized  dose  pole  with  single  600  mg  (height:  99–110  cm),  ¾ (height:  83–99 cm)
and  ½ (height:  66–83  cm)  tablet  divisions,  also  reduces  drug  waste  and  facilitates  inclusion
of preschool-aged  children.  Our  ﬁndings  also  have  bearings  on  the  use  of  other  dose  poles
for treatment  of  young  children.
yal Soc© 2012 Ro
. Introduction
Since 2003, several mass drug administration (MDA)
ampaigns have been implemented in sub-Saharan Africa
reating millions of school-aged children for schistosomi-
sis with praziquantel (PZQ). While these campaigns are
aving an enormous impact in reducing the morbidity suf-
ered by millions of school-aged children, as an unforeseen
onsequence of current treatment guidelines and opera-
ional dosing tools, younger children (≤6 years) have been
onsistently excluded from access to such medication.1–4
While the World Health Organization (WHO) and phar-
aceutical sector consider treatment with PZQ as being
∗ Corresponding author. Tel.: +44 151 705 3724.
E-mail address: jrstoth@liv.ac.uk (J.R. Stothard).
876-3413/$ – see front matter ©  2012 Royal Society of Tropical Medicine and H
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safe for children as young as four years of age, this age-
limit is not yet fully endorsed for ‘off-label’ use of PZQ
in national control programmes settings.5–9 Nonetheless,
as evidence-based advocacy grows this situation is set to
change, for recent reports highlight that egg-patent infec-
tions can be found in children within the ﬁrst year of life in
high transmission settings.3,10–20 Given the young child’s
risk of disease, this current health inequity should not per-
sist. To this end, a signiﬁcant programmatic realignment
could be possible through development of a downward
extension of the current WHO  dosing pole from its present
lowest height limit (i.e., 94 cm).21–23
The idea of dosing PZQ according to height instead
of bodyweight (40 mg/Kg) was  ﬁrst investigated by Hall
et al.24 Two  years later, Montresor et al. expanded on this
concept of using a simple and rudimentary height pole
for pragmatic dosing of PZQ during school-based control
ygiene. Published by Elsevier Ltd. All rights reserved.
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campaigns.25 Since then the WHO  dose pole, now revised
to include children taller than 94 cm,  has become essential
in all campaigns delivering PZQ.26 To cater for the situation
in Uganda where preschool-aged children are consistently
shown to be at risk of infection and in need of treatment,
the PZQ dose pole was extended downwards to include
preschool-aged children (>60 cm tall) with height thresh-
olds for administration of ¾ (84–99 cm)  and ½ (60–84 cm)
tablet divisions; a revised threshold for the administra-
tion of a single tablet (99–110 cm)  was also developed
owing to a previously poorer biometric model ﬁt.27 Whilst
this pole is now regularly used in Uganda, it awaits
endorsement by WHO; theoretical testing using biomet-
ric information from young children in Angola (n = 1067),
Mali (n = 405), Uganda (n = 3238), Sudan (n = 137), Zanzibar
(n = 470) and Zimbabwe (n = 104) has led to good results,
with more than 96% of children receiving acceptable
dosages (30–60 mg/Kg).28–32 Nevertheless, more rigorous
scrutiny of these new height divisions is needed to promote
broader applicability and use in areas outside of Uganda.
The present study was conducted to investigate the
theoretical validity of this extended PZQ dose pole in
a far larger dataset representing 36 African countries.
Importantly, we also used these data to establish a new
biometric model, this time encompassing all 36 African
countries (pan-African model) in an attempt to better cap-
ture inter-country variability in child growth (≤6 years
of age, 55.0–129.9 cm tall, n = 175 276 children), against
which we compared the initial Ugandan biometric model.
The validation of both biometric models was conducted
on height and weight data from 166 210 preschool-aged
children (≤6 years of age, 60–110.0 cm tall).
2. Methods
In order to assemble a large cross-country data set vari-
ous health agencies were ﬁrst contacted with a request for
collation of biometric data from infants and preschool-aged
children across Africa, and with a brief description of how
these data would be used.
2.1. Background information on praziquantel
Praziquantel is commonly marketed in 600 mg  tablets
and treatment is recommended using a regimen of
40 mg/Kg bodyweight in a single dose; an increased
dosage of 60 mg/Kg can be advised in speciﬁc cases.33,34
With PZQ tablets (600 mg)  being available for as little as
US$0.08 each, raw treatment costs per child have reduced
dramatically.33,35
Schistosome worms usually become susceptible to PZQ
6–8 weeks after infection and maturation within the host’s
body. Upon oral administration of PZQ, the drug acts
quickly, typically within one hour, paralysing the worms
and damaging their tegument facilitating immediate death
or immune-dependent killing mechanisms. While there
are reports of side-effects, these are generally mild and
largely transient, although in exceptional cases progression
towards general anaphylaxis can occur.36,37 In certain sit-
uations, where disease transmission is high, a treatmentnal Health 4 (2012) 95– 102
protocol of two  courses of PZQ (40 mg/Kg or higher) sepa-
rated by 2–4 weeks is advocated but not yet fully endorsed
by WHO  as an alternative dosing approach to raise parasito-
logical cure-rates.38–40 In terms of treatment of the younger
child, as detailed pharmacokinetic studies are lacking yet
the need for treatment is clear, a sensible approach would
be to optimise dosing of young children at 40 mg/Kg, with
an acceptable dose ranging from 30–60 mg/Kg until evi-
dence to the contrary is presented.
2.2. Height and weight data
Taking advantage of online databases compiled by
MEASURE (a demographic health surveys data base http://
www.measuredhs.com/start.cfm) population-based data
were obtained on the age, gender, height and weight
of children from 0–6 years of age from countries where
schistosomiasis is endemic (see Figure 1). Data sets are
described in Table 1. Height and weight were recorded
to 0.1 cm and 0.1 Kg accuracy. For Angola and Morocco,
weight was  recorded to 1 Kg and 0.5 Kg accuracy, respec-
tively. Height measurements in infants (<1 year olds)
were conducted as the child was lying down (i.e., length).
Z-scores were constructed using the WHO  (Geneva,
Switzerland) database for child growth standards (2006).
Quality of data was  validated using Z-score calculation;
implausible data were identiﬁed, double-checked and,
if no mistakes were identiﬁed, implausible data were
deleted from the database as they were probably the
result of human error in the ﬁeld or during data entry, i.e.,
weight-for-age Z-scores below –6 and above +5; height-
for-age Z-scores below –6 above +6; weight-for-height and
BMI-for-age Z-scores below –5 and above +5. Furthermore,
only children aged between 6 and 72 months old (i.e.,
55–129.9 cm tall) were included in the primary analysis
in an attempt to establish a new pan-African model (data
from all 36 countries). After all the criteria were met, the
resulting sample size used to establish the pan-African
model was  175 276 children (total censored 5914).
2.3. Analysis
Zanzibari, Angolan and Ugandan biometric data were
collected by the authors during investigative epidemio-
logical surveys using pro-forma data sheets, which were
then entered using EpiData (The EpiData Association,
Odense, Denmark) or Microsoft Excel spreadsheet software
(Microsoft Corp., Redmond, WA,  USA).
For data compiled using MEASURE, biometric records
were downloaded from the website and compiled using
Stata version 11.0 (StataCorp, College Station, TX, USA),
whereby the relevant columns were extracted into a
Microsoft Excel ﬁle (.csv format): country code, gender,
age, weight (in Kg), height (in mm),  year of measurement
and method of measurement (lying down or standing).
The data thus collated were analysed using the R statis-
tical package® v 2·10·1 (The R Foundation for Statistical
Computing, Vienna, Austria) and Microsoft Excel software.
For percentage values (prevalence of children receiving a
dose), 95% CIs were estimated using the exact method.41
Percentage of children receiving a certain dose according to
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migure 1. Maps illustrating schistosomiasis-endemic regions (left) a
atterns of schistosomiasis endemicity was gathered from the ma
ttp://www.path.cam.ac.uk/∼schisto/index.html).
oth dose poles was compared using (one-tailed) Fisher’s
xact modiﬁcation of the 2 × 2 2 test.42 Univariate mod-
ls (height vs weight) were established (linear, polynomial,
ogarithmic and exponential) and model comparisons were
onducted using Akaike information criterion (AIC).43 For
ore details on how models were established and com-
ared see Hall et al.24
Once established, the original Ugandan (weight =
.0029x2 − 0.2817height + 14.526) and the pan-African
odels (weight = 0.2268height – 7.6172) were theoretically
pplied to a subset of the initial population of preschool-
ged children (0–6 years of age), this time ranging only
rom 60–110 cm tall.27 A 60 cm lower limit was used since
his is the lower limit set by the current Ugandan model for
 tablet administration.27,30 An upper limit of 110 cm was
sed since this is the threshold established for 1½ tablets
y the current WHO  dose pole.25 All 36 datasets were uni-
ed into a single pan-African dataset and the resulting
ample size was 166 210 children, i.e., 175 276 children
55.0–129.9 cm tall) made up the complete dataset used
o establish the pan-African model and 166 210 children
60–110 cm tall) made up the subset on which both models
ere tested.
For each model, the following parameters were calcu-
ated: the mean dosage given (and standard deviation),
he number and percentage of children receiving less than
0 mg/Kg (sub-curative dose), the number and percent-
ge of children receiving 30–39 mg/Kg (sub-optimal but
cceptable dosage), the number and percentage of chil-
ren receiving 40–49 mg/Kg (optimal dose), the number
nd percentage of children receiving 50–60 mg/Kg (opti-
al  dose), the number and percentage of children receiving
ore than 60 mg/Kg (overdosed).31,32
. ResultsThe Ugandan model was established using a dataset
f 1046 Ugandan preschool-aged children.27 Using this
odel to estimate dose of PZQ according to the height ofntries from which data were obtained (right). Information on the
sented by Schistosomiasis Research Group at Cambridge, UK (see
preschool-aged African children (n = 166 210) resulted in
58.2% (95% CI 58.0–58.5%) children receiving an optimum
dosage (40–60 mg/Kg), while 95.3% (95% CI 95.2–95.4%)
received an acceptable dosage (30–60 mg/Kg). Importantly,
only 1.6% (95% CI 1.55–1.66%) of children would have
received a sub-curative dosage (<30 mg/Kg), and 3.0% (95%
CI 3.01–3.18%) would have received a slight over-dosage
(>60 mg/Kg) (see Table 2).
The pan-African model was  established using the com-
plete dataset (55–129.9 cm,  ages 6–72 months, n = 175 276
children). A linear model ﬁtted to the height and weight
data from all these children was found to be the most effec-
tive at describing the variability in the data: weight = 0.2268
height – 7.6172. Other univariate models attempted, which
remained unselected by the AIC method, included
polynomial, logarithmic and exponential (data not
shown).
Using this model to estimate dosage of PZQ accord-
ing to the height of the child (n = 166 210, height range
60.0–110.0 cm)  resulted in 50.9% (95% CI 50.7–51.1%) chil-
dren receiving an optimum dosage (40–60 mg/Kg), while
95.6% (95% CI 95.5–95.7%) received an acceptable dosage
(30–60 mg/Kg). Of note is the fact that while the Ugan-
dan model performed signiﬁcantly better at estimating
optimum dosages when compared to the pan-African
model (58.2% vs 50.9%, respectively, p < 0.0001), the pan-
African model was signiﬁcantly better when considering
an overall performance (95.6 vs 95.3%, p < 0.0001). Impor-
tantly, according to the pan-African model, only 2.7% (95%
CI 2.62–2.78%) of children would have received a sub-
curative dosage (<30 mg/Kg), and 1.7% (95% CI 1.62–1.74%)
would have received a slight over-dosage (>60 mg/Kg)
(see Table 2). These values are signiﬁcantly different from
those achieved by the Ugandan model, whereby the Ugan-
dan model estimated signiﬁcantly more over-dosage (3.0
vs 1.7%, p < 0.0001) and signiﬁcantly fewer sub-curative
dosages (1.6 vs 2.7%, p < 0.0001).
Figure 2 shows the distribution (percentage of children)
of height-determined dosages achieved by both models
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Table  1
Description of data sets analysed for standardised height-based praziquantel treatment schedule
Data set Source population Sample size
(55-129.9 cm)
Sample size
(60-110 cm)
Angola malaria, neglected tropical disease and
malnutrition survey, 2010a
Angola
Ages 1–72 months
1 067 992
Benin  demographic and health survey-V, 2006b Benin
Ages 0–48 months
13 323 12 156
Burkina Faso demographic and health
survey-IV, 2003b
Burkina Faso
Ages 0–48 months
8 761 8 150
Burundi demographic and health survey-I,
1997b
Burundi
Ages 0–36 months
1 936 1 857
Cameroon demographic and health survey-IV,
2004b
Cameroon
Ages 0–48 months
3 317 3 061
Chad demographic and health survey-IV, 2004b Chad
Ages 0–48 months
4 636 4 324
Comoros Islands demographic and health
survey-III, 1996b
Comoros Islands
Ages 0–24 months
994 881
Congo  (Brazzaville) demographic and health
survey-V, 2005b
Congo (Brazzaville)
Ages 0–48 months
4 054 3 709
Congo Democratic Republic demographic and
health survey-V, 2007b
Congo DR
Ages 0–48 months
3 564 3 287
Côte  d’Ivoire demographic and health
survey-III, 1998–1999b
Côte d’Ivoire
Ages 0–48 months
1 586 1 480
Egypt demographic and health survey-V, 2005b Egypt
Ages 0–48 months
13 113 11 851
Ethiopia demographic and health survey-IV,
2000b
Ethiopia
Ages 0–48 months
4 129 3 872
Ghana demographic and health survey-V,
2008b
Ghana
Ages 0–48 months
2 482 2 345
Kenya demographic and health survey-V,
2008-2009b
Kenya
Ages 0–48 months
5 315 4 927
Lesotho demographic and health survey-VI,
2009b
Lesotho
Ages 0–48 months
1 674 1 540
Liberia demographic and health survey-V,
2007b
Liberia
Ages 0–48 months
4 508 4 209
Madagascar demographic and health
survey-IV, 2003–2004b
Madagascar
Ages 0–48 months
4 691 4 287
Malawi demographic and health survey-IV,
2004b
Malawi
Ages 0–48 months
8 573 7 877
Mali  demographic and health survey-V, 2006b Mali
Ages 0–48 months
11 517 10 595
Morocco demographic and health survey-IV,
2003–2004b
Morocco
Ages 0–48 months
5 643 5 260
Mozambique demographic and health
survey-IV, 2003b
Mozambique
Ages 0–48 months
8 252 7 487
Namibia demographic and health survey-V,
2006–2007b
Namibia
Ages 0–48 months
3 802 3 496
Niger  demographic and health survey-V, 2006b Niger
Ages 0–48 months
3 849 3 563
Nigeria demographic and health survey-V,
2008b
Nigeria
Ages 0–48 months
21 850 19 701
Rwanda demographic and health survey-V,
2005b
Rwanda
Ages 0–48 months
3 747 3 448
São  Tomé & Príncipe demographic and health
survey-V, 2008–2009b
São Tomé & Príncipe
Ages 0–48 months
1 614 1 474
Senegal demographic and health survey-IV,
2005b
Senegal
Ages 0–48 months
2 920 2 707
Sierra Leone demographic and health
survey-V, 2008b
Sierra Leone
Ages 0–48 months
2 250 2 058
Swaziland demographic and health survey-V,
2006–2007b
Swaziland
Ages 0–48 months
2 085 1 955
Tanzania demographic and health survey-VI,
2010b
Tanzania
Ages 0–48 months
6 919 6 396
Togo  demographic and health survey-III, 1998b Togo
Ages 0–48 months
3 747 3 372
Tunisia demographic and health survey-I,
1988b
Tunisia
Ages 0–36 months
2 033 1 978
Uganda schistosomiasis in mothers and infants
(SIMI) project, 2009–2010c
Uganda
Ages 6–72 months
3 302 2 683
Zambia demographic and health survey-V,
2007b
Zambia
Ages 0–48 months
5 344 4 962
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Table 1 (Continued )
Data set Source population Sample size
(55-129.9 cm)
Sample size
(60-110 cm)
Zanzibar urinary schistosomiasis control
programme monitoring, 2006d
Zanzibar
Ages 0–72 months
470 443
Zimbabwe demographic and health survey-V,
2005-2006b
Zimbabwe
Ages 0–48 months
4 121 3 827
TOTAL Ages 0–72 months 175 276 166 210
a Centro de Investigac¸ ão em Saúde em Angola (CISA), Bengo, Angola.
b Measure/DHS+, ORC Macro International, USA.
c Ugandan Ministry of Health and Natural History Museum (London).
d Zanzibar Ministry of Health and Natural History Museum (London).
Table 2
Performance of the models in estimating praziquantel dosages in 166 210
preschool-aged children (≤6 year olds) from 36 African countries (height
range 60–110 cm). A praziquantel optimal dose was deﬁned as being from
40–60 mg/Kg and an acceptable dosage as being from 30–60 mg/Kg
Ugandan model Pan-African model
Dose
Average (SD) in mg/Kg 42.8 (7.8) 41.0 (6.8)
n (%) of people receiving:
<30 mg/Kga 2 672 (1.6) 4 494 (2.7)
30–39 mg/Kga 61 614 (37.1) 74 316 (44.7)
40–49 mg/Kga 80 267 (48.5) 76 084 (45.8)
50–60 mg/Kga 16 506 (9.9) 8 529 (5.1)
>60 mg/Kga 5 151 (3.0) 2 787 (1.7)
Acceptable dosagea 95.3% 95.6%
Optimal dosea 58.2% 50.9%
S
a
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(D: standard deviation.
indicates the two  performances were signiﬁcantly different (p < 0.05).
n = 166 210). Both data resemble normal distributions
round the target of 40 mg/Kg, albeit skewed to the right
or the Ugandan model indicating a minor tendency
o slightly over-dose. Supplementary Tables 1 and 2
rovide information on country- and region-speciﬁc
erformance of the Ugandan and pan-African models,
espectively.
igure 2. Distribution (percentage of children) of height-determined
osages for children aged 6–72 months receiving praziquantel tablets
sing a standardised schedule according to the two models tested
n  = 166 210).4. Discussion
As MDA-based control programmes are rolled-out
throughout Africa offering PZQ, most of the monitor-
ing and evaluation efforts, as well as applied scientiﬁc
research, is being directed towards understanding pre- and
post-treatment disease dynamics. If MDA  is to become
the principal way  by which we combat schistosomia-
sis, and preschool-aged children are still excluded from
the target demographics of current MDA  efforts, these
research and control activities are perpetuating a health
inequality and failing to protect those most vulnerable
to future ill-health and morbidity. New focus is therefore
needed on understanding how schistosomiasis is already
affecting younger children (<94 cm), developing appro-
priate control tools and promotion of formal targeting
within current control programmes, especially where pro-
grammatic integration with control of other neglected
tropical diseases is needed.3,10–20 An applied research
agenda which perhaps should have beneﬁted by the atten-
tion of SCORE (Schistosomiasis Consortium for Operational
Research and Evaluation - see http://score.uga.edu/)  that
aimed to answer strategic questions about schistosomiasis
control and elimination, but an opportunity unfortunately
now missed.
4.1. An extended praziquantel dose pole
This study suggests that in order to permit inclusion of
younger children in pragmatic dosing of PZQ, downward
extension of the current dose pole is required. The two
biometric models tested here have their strengths and
weaknesses. While the Ugandan model is capable of pre-
dicting more optimum dosages (58.2% of children receiving
40–60 mg/Kg), the pan-African model correctly predicted
more acceptable dosing (95.6% of children receiving
30–60 mg/Kg) covering a range from 6-months to 6 years
of age. Importantly, even though the genesis populations
differ in size (n = 1046 for the ﬁrst and n = 175 276 for the
second) and origin, both models result in fairly similar dose
poles. In fact, both models support the need for an upward
revision of the current single tablet lower threshold from
94 cm to 99 cm.27,30 According to the Ugandan model, the
height-intervals for ½ tablet and ¾ tablet divisions should
be 60–84 cm and 84–99 cm,  corresponding to a mean age of
1 year and 2¾ years, respectively.27 The 36-country model,
on the other hand, corrected the lower limit for ¾ tablet
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Figure 3. Pictorial representation of the current WHO  dose pole for administration of praziquantel tablets (at 600 mg each) (left) and the new dose poles -
Ugandan model (centre) and pan-African model (right) with new height thresholds added to allow for treatment of preschool-aged children (<6 year olds).
 from 94Additionally, the WHO  pole’s single tablet lower limit has been corrected
of  a ¾ tablet division rather than a single tablet.
division (now 83–99 cm)  and raised the lower height-limit
eligible for treatment using a dose pole (66–83 cm for
½ tablet division). For a pictorial representation of the
current WHO  dose pole, as well as the dose poles predicted
by the two models tested here see Figure 3.
Choosing which model, i.e., which dose pole, should
be implemented requires a discussion of selection criteria.
For example, one is capable of predicting more optimum
dosages (Ugandan model), while the other performs better
overall (pan-African model) across assembled countries.
However, at the international level we propose that the
pan-African model is the favoured option since its gen-
esis population is far larger and more representative of
the pan-African population, which will be treated by any
future extended dose pole to be endorsed by WHO. The
pan-African model presented here does not adjust for
any variation in the height data between countries; this
variation is implied in the database, and by considering
all countries as one single database we hoped to control cm to 99 cm by both models. The illustrated child needs administration
implicitly for this variation. Of note is the fact that both
models have been tested for each country individually and
both models were found to perform signiﬁcantly differ-
ently for each region of Africa (Supplementary Tables 1 and
2). More particularly, each model performed similarly in
Southern, Central and Eastern Africa, while showing very
different performances for Western and Northern Africa.
4.2. Health and economic impact of a revised dose pole
Without a doubt, treating children at a younger age
with PZQ can lead to signiﬁcant decreases in overall
infection intensities, as well as prevalence levels in chil-
dren as they progress to school-age.29 This is important
considering the purpose of current control programmes
(i.e., morbidity control: dampening the occurrence of
raised infection intensities). Therefore treatment of chil-
dren at an earlier age can result in earlier reductions in
egg-counts and disease-progression.29,44 Also, by negating
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atural transmission from an earlier age and preventing
igh worm burdens, treatment of younger children could
ead to long-term economic savings as younger children
equire fewer tablets. Treating younger children could be
 sensible future strategic realignment of MDA, building
or longer-term sustainability over forthcoming decades,
s the treatment needs in older children are set to decline.
There are also immediate economic savings to be con-
idered if the current WHO  dose pole is revised to start
reatment with a single tablet at 99 cm and not the cur-
ent 94 cm.  Pharmaceutical companies are now engaged
o provide large tablet procurements/donations to control
rogrammes (see London Declaration on Neglected Trop-
cal Diseases in http://www.unitingtocombatntds.org/),
eaning drug wastage has become an important issue,
nd using the new height threshold of 99 cm could lead to
igniﬁcant savings of tablets (and money).29,30 In our sam-
le of 166 210 children, 11.3% (18 806) were between 94
nd 99 cm tall (ages between 2 and 5 years, mean age of
.9 years). Using the corrected height threshold (99 cm)
ather than the original one (94 cm)  would have resulted in
aving some 4700 tablets. While this level of drug wastage
ight appear negligible, extrapolating this continent-wide
eveals its importance, with millions of children currently
iving in endemic areas.
. Conclusions
Following on from a comprehensive biometric investi-
ation, two models for creation of an extended PZQ dose
ole for younger children were validated against an exten-
ive database of 166 210 preschool-aged children (≤6 years
f age, 60.0–110.0 cm tall) from 36 countries in Africa.
ownward extension and optimization of present height
hresholds of the current WHO  dose pole for administra-
ion of a single 600 mg  tablet (height: 99–110 cm), as well
s ¾ (height: 83–99 cm)  and ½ (height: 66–83 cm)  tablet
ivisions reduces drug waste and allows for inclusion of
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